Sponsor

Chugai Pharmaceutical

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Chugai Pharmaceutical appears in 34 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials34
Recruiting shown4
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

34 shown
AQUA07 in Patients With ALK-Positive Non-Small Cell Lung CancerNCT07617337 · lead sponsor · 2026-07-24
RECRUITING
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCERNCT07107490 · lead sponsor · 2025-10-08
RECRUITING
The Biomarker Exploratory Study in Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04818983 · lead sponsor · 2021-04-07
COMPLETED
Prospective Multicenter Observational Study of Atezolizumab Combination Therapy in Lung Cancer (J-TAIL-2)NCT04501497 · lead sponsor · 2020-08-21
COMPLETED
A Study of Atezolizumab in Patients With Unresectable, Locally Advanced or Metastatic NSCLC (J-TAIL)NCT03645330 · lead sponsor · 2018-08-15
COMPLETED
A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease PatientsNCT01656525 · lead sponsor · 2012-06-01
COMPLETED
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics/Pharmacodynamics (PK/PD) of Ocrelizumab in Patients With Rheumatoid ArthritisNCT00779220 · lead sponsor · 2008-10-01
TERMINATED
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.)NCT00661284 · lead sponsor · 2008-04-01
COMPLETED
Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast CancerNCT00467012 · lead sponsor · 2007-04-01
COMPLETED
PhaseⅢOpen-label Study of MRA for Rheumatoid Arthritis(RA)NCT00380601 · lead sponsor · 2006-05-01
COMPLETED
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JPNCT00144586 · lead sponsor · 2005-03-01
COMPLETED
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)NCT00144560 · lead sponsor · 2005-02-01
COMPLETED
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal ImpairmentNCT00144573 · lead sponsor · 2005-01-01
COMPLETED
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JPNCT00144534 · lead sponsor · 2004-06-01
COMPLETED
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JPNCT00144547 · lead sponsor · 2004-04-01
COMPLETED
Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA)NCT00144521 · lead sponsor · 2004-02-01
COMPLETED
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)NCT00144508 · lead sponsor · 2003-03-01
COMPLETED
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone MetastasesNCT00060138 · lead sponsor · 2002-11-01
COMPLETED
Study of MRA in Patients With Rheumatoid Arthritis (RA)NCT00144651 · lead sponsor · 2001-08-01
COMPLETED
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · collaborator · 2025-10-24
RECRUITING
Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBCNCT06793553 · collaborator · 2024-09-13
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung CancerNCT06497556 · collaborator · 2024-09-23
ACTIVE_NOT_RECRUITING
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010NCT05867121 · collaborator · 2023-10-02
COMPLETED
Satralizumab in the Treatment of Pulmonary Arterial Hypertension (SATISFY-JP Trial)NCT05679570 · collaborator · 2022-07-12
COMPLETED
A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast CancerNCT04732598 · collaborator · 2021-01-21
COMPLETED
A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerNCT03726879 · collaborator · 2019-01-11
COMPLETED
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast CancerNCT02514681 · collaborator · 2015-08-01
COMPLETED
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast CancerNCT01989780 · collaborator · 2014-01-01
COMPLETED
Phase I Trial of VS-6766 Alone and in Combination With EverolimusNCT02407509 · collaborator · 2013-06-17
COMPLETED
Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency of Depression in Rheumatoid Arthritis (RA) ParticipantsNCT02485483 · collaborator · 2012-11-01
COMPLETED
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen TreatmentNCT00237198 · collaborator · 2004-03-01
COMPLETED
Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy TreatmentNCT00210249 · collaborator · 2002-09-01
COMPLETED
Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast CancerNCT00237211 · collaborator · 2001-06-01
COMPLETED
Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast CancerNCT00247663 · collaborator · 1999-12-01
COMPLETED

Drugs studied in this sponsor's trials

34 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Chugai Pharmaceutical as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
letrozole4
paclitaxel4
placebo3
atezolizumab2
bevacizumab2
capecitabine2
gemcitabine2
methotrexate2
letrozole RxCUI 72965 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials placebo RxCUI 8375 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 3 trials atezolizumab RxCUI 1792776 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials capecitabine RxCUI 194000 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials gemcitabine RxCUI 12574 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials methotrexate RxCUI 6851 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials pertuzumab RxCUI 1298944 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials trastuzumab RxCUI 224905 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials adagrasib RxCUI 2625882 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial ado-trastuzumab emtansine RxCUI 1371041 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial anastrozole RxCUI 84857 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial carboplatin RxCUI 40048 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial cisplatin RxCUI 2555 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial cyclophosphamide RxCUI 3002 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial doxorubicin RxCUI 3639 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial eribulin RxCUI 1045453 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial everolimus RxCUI 141704 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial exemestane RxCUI 258494 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial fulvestrant RxCUI 282357 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial goserelin RxCUI 50610 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor19
collaborator15
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.